Back to top
more

Neuronetics (STIM)

(Delayed Data from NSDQ)

$3.49 USD

3.49
44,573

-0.03 (-0.85%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.50 +0.01 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

Neuronetics (STIM) Progresses in MRD and TRD With New Deal

The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 26.92% and 2.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

The Cooper Companies (COO) Q1 Earnings and Revenues Top Estimates

The Cooper Companies (COO) delivered earnings and revenue surprises of 7.59% and 1.80%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates

OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates

Artivion (AORT) delivered earnings and revenue surprises of 184.62% and 4.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock?

Neuronetics (STIM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 5% and 3.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 34.48% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers

Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.

LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure

Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.

Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger

Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.

Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture

Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.

Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan

Bruker (BRKR) introduces the timsTOF Ultra mass spectrometer and VistaScan software for enhanced dia-PASEF 4D-Proteomics at the 71st ASMS meeting.

Quest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes

Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.

Bruker's (BRKR) Latest Workflows to Aid Applied Markets

Bruker (BRKR) introduces Novel EVOQ DART-TQ+ for chromatography-free mass spectrometry for applied markets.

Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes

Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.

Neogen (NEOG) Introduces 2 Assays for Histamine Detection

Neogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine.

LabCorp (LH) Expands Precision Oncology With Biopsy Test

The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.

Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23

At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio

Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays

Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.